Investor Presentaiton

Non-Covid revenue on growth trajectory (excl. PPP Contracts & Hi-Tech) METROPOLIS The Pathology Specialist 197 Non-Covid Revenues Q4FY21 v/s Q4FY22 Q4FY21 216 +8% 213 183 Non-Covid Revenues Q1FY22 v/s Q1FY23 Q4FY22 Q1FY22 Non-Covid Revenues Q2FY22 v/s Q2FY23 +13% +21% 222 Q1FY23 Non-Covid Revenues Q3FY22 v/s Q3FY23 243 208 +13% 235 Q2FY22 Q2FY23 Q3FY22 Q3FY23 Key Highlights Non-Covid revenues (excl. Hi-tech) for Q3FY23 stood at Rs. 235 crs as compared to Rs. 208 crs in Q3FY22, a growth of 13% ✓ Covid & Covid allied tests contributed only 3% of revenue in Q3FY23 vs. 21% of revenue in Q3FY22 We have been witnessing a steady growth for our Non-Covid business on a Y-o-Y basis for the last four quarters ✓ As economy moves past the covid days & the gradual shift in the consumer behavior encouraging them to be more health aware and proactive, expect the non-covid revenue to continue the growth trajectory both in the illness & premium wellness segments 8

View entire presentation